Alpha 2.0
Login Register
» Authors » Muntasir M Majumder

Muntasir M Majumder

Explore the profile of Muntasir M Majumder including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 157
Followers 0
Related Specialties
Hematology
Oncology
Science
Top 10 Co-Authors
Caroline A Heckman
Paul Dowling
Despina Bazou
Bhagwan Yadav
Kimmo Porkka
Alun Parsons
Krister Wennerberg
Juho J Miettinen
Ana Slipicevic
Raija Silvennoinen
Published In
Blood
Haematologica
Hemasphere
Oncotarget
Cancers (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
Flanagan K, Kumari R, Miettinen J, Haney S, Varney M, Williams J, et al.
Hemasphere . 2022 Mar; 6(3):e687. PMID: 35243210
Immunoglobulin light-chain (AL) amyloidosis is a rare disease caused by clonal plasma cell secretion of misfolded light chains that assemble as toxic amyloid fibrils, depositing in vital organs including the...
2.
Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
Tierney C, Bazou D, Majumder M, Anttila P, Silvennoinen R, Heckman C, et al.
Sci Rep . 2021 Jun; 11(1):12866. PMID: 34145309
With the introduction of novel therapeutic agents, survival in Multiple Myeloma (MM) has increased in recent years. However, drug-resistant clones inevitably arise and lead to disease progression and death. The...
3.
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
Miettinen J, Kumari R, Traustadottir G, Huppunen M, Sergeev P, Majumder M, et al.
Cancers (Basel) . 2021 Apr; 13(7). PMID: 33810334
Multiple myeloma (MM) is characterized by extensive immunoglobulin production leading to an excessive load on protein homeostasis in tumor cells. Aminopeptidases contribute to proteolysis by catalyzing the hydrolysis of amino...
4.
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
Majumder M, Leppa A, Hellesoy M, Dowling P, Malyutina A, Kopperud R, et al.
Haematologica . 2019 Aug; 105(6):1527-1538. PMID: 31439679
Innate drug sensitivity in healthy cells aids identification of lineage specific anti-cancer therapies and reveals off-target effects. To characterize the diversity in drug responses in the major hematopoietic cell types,...
5.
Dasatinib and navitoclax act synergistically to target NUP98-NSD1/FLT3-ITD acute myeloid leukemia
Kivioja J, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder M, et al.
Leukemia . 2018 Dec; 33(6):1360-1372. PMID: 30568173
Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3-ITD is associated with unfavorable prognosis and represents a particularly challenging treatment group. To identify novel effective therapies for this AML subtype,...
6.
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
Kuusanmaki H, Dufva O, Parri E, van Adrichem A, Rajala H, Majumder M, et al.
Oncotarget . 2017 Dec; 8(57):97516-97527. PMID: 29228628
Constitutive JAK/STAT3 signaling contributes to disease progression in many lymphoproliferative disorders. Recent genetic analyses have revealed gain-of-function mutations in lymphoid cancers leading to hyperactivation of STAT3, which may represent a...
7.
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML
Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa K, Majumder M, et al.
Blood . 2017 Jun; 130(6):789-802. PMID: 28619982
The bone marrow (BM) provides a protective microenvironment to support the survival of leukemic cells and influence their response to therapeutic agents. In acute myeloid leukemia (AML), the high rate...